Silo Pharma Statistics
Total Valuation
Silo Pharma has a market cap or net worth of $2.78 million. The enterprise value is -$2.45 million.
| Market Cap | 2.78M |
| Enterprise Value | -2.45M |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Silo Pharma has 1.59 million shares outstanding. The number of shares has increased by 170.50% in one year.
| Current Share Class | 1.59M |
| Shares Outstanding | 1.59M |
| Shares Change (YoY) | +170.50% |
| Shares Change (QoQ) | +20.19% |
| Owned by Insiders (%) | 0.93% |
| Owned by Institutions (%) | 9.75% |
| Float | 1.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 51.40 |
| Forward PS | n/a |
| PB Ratio | 0.40 |
| P/TBV Ratio | 0.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.36
| Current Ratio | 5.36 |
| Quick Ratio | 4.90 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -112.03 |
Financial Efficiency
Return on equity (ROE) is -91.23% and return on invested capital (ROIC) is -56.89%.
| Return on Equity (ROE) | -91.23% |
| Return on Assets (ROA) | -44.25% |
| Return on Invested Capital (ROIC) | -56.89% |
| Return on Capital Employed (ROCE) | -91.31% |
| Weighted Average Cost of Capital (WACC) | 8.36% |
| Revenue Per Employee | $18,026 |
| Profits Per Employee | -$1.49M |
| Employee Count | 3 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -85.36% in the last 52 weeks. The beta is 0.75, so Silo Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | -85.36% |
| 50-Day Moving Average | 3.09 |
| 200-Day Moving Average | 5.12 |
| Relative Strength Index (RSI) | 22.90 |
| Average Volume (20 Days) | 45,414 |
Short Selling Information
The latest short interest is 29,072, so 1.83% of the outstanding shares have been sold short.
| Short Interest | 29,072 |
| Short Previous Month | 33,208 |
| Short % of Shares Out | 1.83% |
| Short % of Float | 1.85% |
| Short Ratio (days to cover) | 0.24 |
Income Statement
In the last 12 months, Silo Pharma had revenue of $54,077 and -$4.47 million in losses. Loss per share was -$5.07.
| Revenue | 54,077 |
| Gross Profit | -7,987 |
| Operating Income | -4.46M |
| Pretax Income | -4.47M |
| Net Income | -4.47M |
| EBITDA | -4.45M |
| EBIT | -4.46M |
| Loss Per Share | -$5.07 |
Balance Sheet
The company has $5.23 million in cash and no debt, with a net cash position of $5.23 million or $3.29 per share.
| Cash & Cash Equivalents | 5.23M |
| Total Debt | n/a |
| Net Cash | 5.23M |
| Net Cash Per Share | $3.29 |
| Equity (Book Value) | 4.89M |
| Book Value Per Share | 4.33 |
| Working Capital | 4.65M |
Cash Flow
| Operating Cash Flow | -3.34M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 11,750 |
| Net Borrowing | n/a |
| Free Cash Flow | -4.66M |
| FCF Per Share | -$2.93 |
Margins
| Gross Margin | -14.77% |
| Operating Margin | -8,250.46% |
| Pretax Margin | -8,269.53% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Silo Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -170.50% |
| Shareholder Yield | -170.50% |
| Earnings Yield | -160.89% |
| FCF Yield | -167.71% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | -0.05% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 3, 2026. It was a reverse split with a ratio of 1:15.
| Last Split Date | Jun 3, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
Silo Pharma has an Altman Z-Score of -3.34 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.34 |
| Piotroski F-Score | 1 |